Clinical Trial Update: Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pantoprazole in combination with docetaxel for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pantoprazole (pantoprazole)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED